paroxysmal nocturnal haemoglobinuria

News

Novo builds pipeline again with $2.1bn Omeros deal

Novo Nordisk has boosted its pipeline by paying $340m upfront for rights to an Omeros drug for PNH and other rare blood and kidney disorders.

News

Novartis taps Atropos AI for earlier PNH diagnoses

Novartis teams up with real-world evidence specialist Atropos Health, hoping to speed up the diagnosis and treatment of rare disease PNH.

News

ASH: Regeneron plays its PNH hand

Regeneron's Alnylam-partnered poze-cemdi combination achieves greater disease control measured using LDH than AZ's market-leading Ultomiris.

News

Roche's PNH drug PiaSky backed for NHS use by NICE

Roche's PiaSky has been recommended for use by the NHS in England and Wales for the rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH), becoming the first option for patients th

News

Novartis' oral PNH drug Fabhalta rolls out in England, Wales

Novartis' targeted Factor B inhibitor Fabhalta – the first oral monotherapy for rare disease paroxysmal nocturnal haemoglobinuria (PNH) – has been cleared by NICE for use by the NHS in Engl

News

Roche gets EU nod for subcutaneous PNH drug PiaSky

Roche's PiaSky has been approved by the European Commission, becoming the first therapy for rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH) that can be given by monthly subcu

Novo builds pipeline again with $2.1bn Omeros deal

Novartis taps Atropos AI for earlier PNH diagnoses

ASH: Regeneron plays its PNH hand

Roche's PNH drug PiaSky backed for NHS use by NICE

Novartis' oral PNH drug Fabhalta rolls out in England, Wales

Roche gets EU nod for subcutaneous PNH drug PiaSky

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

paroxysmal nocturnal haemoglobinuria

Editor's Picks